Table 1 Patient characteristics and prior therapies.
Patient | Age (years) | Gender | Ig Isotype | ISS at diagnosis | FISH | Number of prior lines of therapy | PI before/after carfilzomib | Previous ASCT (years prior to diagnosis of TMA) |
|---|---|---|---|---|---|---|---|---|
1 | 70 | F | IgGκ | 2 | +1q21; t(4; 14); del17p | 1 | Ixa before/Bor after | N |
2 | 69 | F | IgGκ | 2 | N/A | 2 | Bor before | Y (3) |
3 | 67 | M | IgGλ | 1 | N/A | 2 | Bor before | Y (11) |
4 | 51 | M | IgGκ | 3 | N/A | 1 | Bor before | Y (1) |
5 | 66 | M | IgGκ | 3 | +1q21; del13q; del17p | 1 | Ixa before /Bor after | N |
6 | 70 | F | IgGλ | 3 | 1q21 | 1 | Bor before | Y (4) |
7 | 55 | M | IgGλ | 1 | N/A | 5 | Bor before | Y (12) |
8 | 73 | M | IgGλ | 3 | Normal | 1 | Bor before | Y (4) |
9 | 73 | F | IgGλ | 3 | +1q21 | 5 | Bor before | N |
10 | 47 | M | IgGλ | 2 | t(11;14) | 3 | Bor before | Y (2) |
